Noven Appoints Dolores Calicchio as
Vice President of Human Resources

Noven Pharmaceuticals, Inc. today announced the appointment of Dolores Calicchio as the company’s new Vice President of Human Resources, succeeding Lance Williams, who will be retiring in April. In this role, Calicchio will lead and be responsible for all human resources activities impacting Noven’s workforce across the U.S.

Calicchio has more than 20 years of experience in the pharmaceutical and other industries. Prior to joining Noven, Calicchio served as the Vice President of Human Resources at Carnival Cruise Lines. Previously, she held positions of Vice President for Global Pharmaceutical Supply Group and Vice President for Johnson & Johnson Health Care Systems, as well as leadership positions in human resources at Merck.

As Noven’s Vice President of Human Resources, Calicchio will report directly to Noven’s Chief Executive Officer, Jeff Mihm. Regarding Calicchio’s appointment, Mihm said: “We are pleased and excited to welcome Dolores to Noven. Dolores brings extensive experience in the pharmaceutical industry, and we expect her strong background across a broad range of HR competencies will help us achieve our long-term goals and those of our parent company, Hisamitsu.”

 

About Noven
Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of prescription pharmaceutical products. Noven’s mission is to develop and offer pharmaceutical products that meaningfully benefit patients around the world, with a commitment to advancing patient care through transdermal drug delivery. Noven is a stand-alone operating subsidiary of Japan-based Hisamitsu Pharmaceutical Co., Inc., serving as Hisamitsu’s U.S. platform in prescription pharmaceuticals, and helping Hisamitsu bring the benefits of patch therapy to the world. For more information about Noven, visit www.noven.com. For information about Hisamitsu, visit www.global.hisamitsu.

Contact:
Stephanie Lamenta
Noven Pharmaceuticals, Inc.
305-253-1916